Navigation Links
UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
Date:10/11/2007

BERKELEY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced results from a Phase 1a clinical study of CD-NP, Nile's selective NPR-B agonist being developed for the treatment of heart failure. The results of this study will be included in the Company's presentation today at the BIO Investor Forum in San Francisco, CA.

"The development of a peptide that has natriuretic and renal effects, with relatively little effect on blood pressure, is a potentially important achievement. The results of this trial in healthy volunteers have confirmed some of the hypotheses developed during the pre-clinical studies. We were particularly interested to see a clear, dose dependent increase in cGMP, which suggests the molecule activates the NPR receptors," commented Dr. Barry Massie, Professor of Medicine, University of California, San Francisco, Chief, Cardiology Section, San Francisco VA Hospital, and member of Nile's scientific advisory board.

Study Design

The Phase 1a study was conducted to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of various doses of CD-NP compared to placebo over a four-hour infusion in 22 healthy volunteers. The study evaluated several pharmacodynamic variables which may translate into safety and efficacy in the heart failure population. Nile measured the effect of CD-NP on systemic blood pressure, urinary flow rate, urinary sodium excretion, serum potassium, renal function and cGMP, a secondary messenger of the target receptor and indicator of in-vivo activity.

Study Results

CD-NP was well tolerated with no serious adverse events and all subjects completed the four-hour infusion of placebo, 10, 17.5 or 25 ng/kg/min of CD-NP.

With respect to clinical and biomarker assessments, CD-NP (placebo, 10, 17.5 and 25 ng/kg/min) increased urine flow rate versus baseline (125%, 53%, 30% and 230% average change, respectively), increa
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014  Wearable sports and activity ... less than two years, producing a massive amount ... huge opportunity exists for leveraging this data to ... ) introduced a first-of-its-kind wearable analytics platform for ... of clinical research linking activity and health risks, ...
(Date:9/16/2014)... Sept. 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), ... of chronic pain, announced today that it has entered ... (MSKCC) in a series of animal studies for levorphanol, ... extended release form of levorphanol.  Gavril Pasternak, MD, PhD, ... Dr. Pasternak said, "Levorphanol is a ...
(Date:9/16/2014)... 2014 Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, ... Stanley M. Bergman, Henry Schein,s Chairman of the Board and ... services panel at the Leerink Partners Services Roundtable on Tuesday, ... Dr. Stohler, Dean of Columbia University,s College of ...
Breaking Medicine Technology:Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Henry Schein To Present At The Leerink Partners Services Roundtable 2
(Date:9/16/2014)... York, NY (PRWEB) September 16, 2014 After ... program as one of the premier fertility centers in the ... Paul Gindoff have returned to their hometown of New York ... with Chelsea IVF and Genetics Labs. , Chelsea Fertility ... of becoming a parent in the New York Tri-State Area, ...
(Date:9/16/2014)... New York, NY (PRWEB) September 16, 2014 ... they are actually hungry, but for comfort during times ... consist of fatty, sugar laden treats that may provide ... as well as sabotaging the best laid weight loss ... Diet Plans that provide patients with the skills ...
(Date:9/16/2014)... YELM, Washington (PRWEB) September 16, 2014 ... to attend the Capstone Event in Yelm, Washington, Oct. ... event finishes the year and caps off the remarkable ... around the world in Switzerland, Italy, Australia, South Korea, ... is $1000, half price for children ages 6-19 and ...
(Date:9/16/2014)... 2014 With Pfister Energy Inc as ... Antonio, TX. has been awarded a solar technology contract ... US, including Alaska and Hawaii, U.S. Territories and the ... (EITF) and the Corps of Engineers, Engineering and Support ... to fund renewable and alternative energy projects greater than ...
(Date:9/16/2014)... 2014 Dr. Randy Carlson and ... the Love Your Marriage event is coming to ... helping married couples to better communicate, increase intimacy and have ... evening of fun, encouragement and learning to strengthen your marriage ... 26 – Living Word Bible Church (Mesa), Saturday, Sept. 27 ...
Breaking Medicine News(10 mins):Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 2Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 3Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 4Health News:Diet Doc Announces Emotional Eaters Diet Plans to Help Patients Break the Cycle for Fast and Permanent Weight Loss 2Health News:Diet Doc Announces Emotional Eaters Diet Plans to Help Patients Break the Cycle for Fast and Permanent Weight Loss 3Health News:Ramtha School Presents Capstone Event in Yelm Oct. 20-26 2Health News:Solar Construction Opportunity at U.S Army Installations Awarded to Pfister Energy & Infinity Development 2Health News:The Intentional Living Center Introduces the Love Your Marriage Night Featuring Dr. Randy Carlson in Arizona 2
... number of Australian HIV cases in the past seven years ... in men having sex with men, and some clear geographic ... research published online for the Medical Journal of Australia. ... at the National Centre in HIV Epidemiology and Clinical Research ...
... of quitting smoking, but are prepared to try and lessen ... ,However, after studying healthcare literature, a team of Cochrane ... to this alternative of cutting down the number of cigarettes. ... has been at helping them to stop smoking completely. But, ...
... Researchers have revealed that combining a non-pyrethroid insecticide, ... to be an effective insecticide-repellent synergy against ... ,A combination of the two had proved ... addition of their respective properties. Mosquito nets soaked ...
... Research Foundation (MDRF), in collaboration with the U.K.-based Oxford ... Centre in Chennai . ,For the people ... products, this is a significant development. For now scientific ... Index (the metabolic speed at which food is converted ...
... a sensible diet, exercise and weight control helps people ... Howard Hughes Medical Institute have found that all these ... pathway in the brain. ,This insulin-like pathway ... body. The pathway is activated when insulin and insulin-like ...
... linked bipolar disorder or manic depression with accelerated shrinking of ... condition defined as recurrent episodes of significant disturbance in moods. ... researchers led by Dr. Andrew McIntosh at the University of ... the grey matter in the brain of people with bipolar ...
Cached Medicine News:Health News:HIV Cases Increasing In Australia 2Health News:Chain Smokers Prepared to Lessen Their Daily Cigs Rather Than Quitting 2Health News:Insecticide and Repellent Combo Effective in Eliminating Malarial Mosquitoes 2Health News:A Centre for Glycemic Index Testing Opened in Chennai 2Health News:Sensible Diet, Exercise and Weight Control Increases Longevity 2Health News:Sensible Diet, Exercise and Weight Control Increases Longevity 3
... The Veris physiological monitor offers a comprehensive ... specifically designed for pediatric and neonate patients, ... to 3T. Veris is the first MR ... of pediatric and neonate patient monitoring. The ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
... is a fully automated ... for clotting, photometric and ... tests.The medium-throughput analyser offers ... tubes, 45 reagents onboard, ...
Medicine Products: